Oncogene-induced senescence is a mechanism of tumor suppression that restricts the progression of benign tumors. Important advances have been made toward elucidating the mechanisms that regulate this response; however, there is presently no unified model that integrates all current findings. DNA damage, replicative stress, reactive oxygen species, heterochromatin formation and negative feedback signaling networks have all been proposed to play an integral role in promoting senescence in response to various oncogenic insults. In all cases, these signals have been shown to function through Rb and p53, but utilize different intermediaries. Thus, it appears that senescence is not triggered by a single, linear series of events, but instead is regulated by a complex signaling network. Accordingly, multiple proteins may cooperate to establish a senescence response, but the limiting signal(s) may be dictated by the initiating genetic alteration and/or tissue type. This review will focus on integrating current models and will highlight data that provide new insight into the signals that function to suppress human tumor development. Oncogene (2008) 27, 2801-2809; doi:10.1038/sj.onc.1210950; published online 14 January 2008
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History of oncogene-induced senescence
Our ideas regarding the biological consequences of aberrant Ras activation have evolved considerably over the years. In 1982, ras was identified as a human oncogene and activated Ras proteins were shown to be capable of transforming immortalized rodent cells (Der et al., 1982; Parada et al., 1982) . However, even at this time, additional cooperating genetic alterations were known to be required for Ras to transform primary cells (Land et al., 1983) . Studies described in 1997 provided an explanation for this finding when it was shown that in wild-type cells, activated Ras actually triggered an initial wave of proliferation, followed by an irreversible growth arrest known as cellular senescence and a concomitant accumulation of p53 and p16 proteins (Serrano et al., 1997) . Accordingly, Ras-induced senescence could be bypassed by inactivating the Rb and p53 pathways, suggesting that this response may have evolved as a mechanism of tumor suppression. Importantly, these observations provided a basis for understanding the cooperativity of these genes in human cancer.
Despite these observations, the physiological relevance of oncogene-induced senescence was debated for several years. Opponents of the concept speculated that it might be an in vitro phenomenon caused by supraphysiological levels of activated Ras. This hypothesis was fueled by the development and characterization of mouse models that were designed to express a single activated K-ras allele driven by its endogenous promoter (Guerra et al., 2003; Tuveson et al., 2004) . Initial reports demonstrated that this allele promoted hyperplasia and tumor development in a subset of tissues. Moreover, this allele did not induce the cellular senescence of mouse embryonic fibroblasts (MEFs), but rather resulted in their immortalization, supporting the possibility that at least in this cell type, senescence might be an artifact of Ras overexpression (Tuveson et al., 2004) .
However, several reports have now demonstrated that oncogene-induced senescence does indeed occur in vivo in human tumors and in mouse tumor models (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou et al., 2005; Courtois-Cox et al., 2006; Dankort et al., 2007; Sarkisian et al., 2007) . Collectively, investigators have observed that mutations in K-ras, B-raf, PTEN and NF1 can trigger cellular senescence in vivo. Moreover, senescence occurs in benign but not in advanced tumors, supporting the in vitro observation that activation of these pathways leads to an initial burst of proliferation followed by cellular senescence. Together, these data support the conclusion that senescence functions to suppress tumor development by preventing the progression of these benign lesions in the absence of additional cooperating mutations. These findings have also provided the biological imperative to elucidate the mechanisms that regulate this protective response. In doing so, it is likely that new genes that suppress human tumor development will be identified.
How does senescence suppress tumor development?
Apoptosis has been a widely accepted mechanism of tumor suppression for over a decade (Brown and Attardi, 2005; Kim et al., 2006) . The means by which it suppresses tumor development is intuitive: apoptotic cells die and are physically eliminated. However, there has been more resistance to the concept that senescence functions in a similar capacity. The observation that senescent cells accumulate in benign human tumors strongly supports the hypothesis that senescence restricts tumor progression. However, several studies have now established a more causal role for senescence in this process (Sarkisian et al., 2007; Ventura et al., 2007; Xue et al., 2007) . First, while senescence has been historically defined as 'irreversible', until recently, evidence of its irreversibility in vivo has been lacking. By using a transgenic mouse model designed to express a doxycylineregulated mutant H-ras allele, Sarkisian et al. (2007) have now shown that once senescence is triggered, cells are not capable of re-entering the cell cycle or developing into tumors. Using a different genetic approach, two other studies have demonstrated that the acute re-expression of endogenous p53 rapidly induces senescence and halts tumorigenesis in genetically engineered mouse models of hepatocellular carcinoma and sarcoma (Ventura et al., 2007; Xue et al., 2007) . Xue et al. further showed that even a brief reactivation of p53 is sufficient to trigger this irreversible response. Moreover, these lesions ultimately regressed, at least in part due to clearance mediated by an innate immune response. However, it remains to be determined whether other mechanisms also participate in tumor regression. In addition, it will be important to establish how some senescent cells (for example, cells within benign lesions) may evade mechanisms leading to their elimination. Nevertheless, all three reports have provided important evidence that senescence does suppress tumorigenesis in vivo.
Does signal intensity or cell type matter?
Another apparent discrepancy has also been clarified by recent studies. As noted earlier, one of the initial hurdles in accepting senescence as a mechanism of tumor suppression was the concern that perhaps only nonphysiological levels of activated Ras could trigger this response. This skepticism was fueled by the observation that while MEFs senesce in response to overexpressed oncogenic Ras, MEFs expressing a single activated K-ras allele are immortal (Tuveson et al., 2004) . However, now, it has been shown that a subset of adenomas from these same mice do undergo senescence in vivo (Collado et al., 2005) , raising the possibility that different cell types may be differentially sensitive to the same signal. This hypothesis has been formally proven by analysing the consequences of inactivating the NF1 tumor suppressor, the gene responsible for the familial cancer syndrome neurofibromatosis type I (NF1) (Courtois-Cox et al., 2006) . NF1 encodes a RasGAP protein, and its inactivation has been shown to cause an acute activation of (endogenous) Ras and Ras effector pathways (Basu et al., 1992; DeClue et al., 1992) . Similar to MEFs expressing a single activated K-ras allele, inactivation of NF1 via shRNA constructs results in the immortalization of this cell type (Courtois-Cox et al., 2006) . In contrast, NF1 ablation rapidly triggers cellular senescence of normal human diploid fibroblasts. Importantly, NF1 deficiency also induces senescence in vivo, in cells within benign human tumors from patients with NF1. Therefore, it can be concluded that (1) oncogene-induced senescence is not an artifact of Ras overexpression and (2) different cell types exhibit different sensitivities to oncogenic stress. The challenge of the future will be to elucidate the mechanisms that dictate the sensitivity or resistance to a specific oncogenic signal.
Nevertheless, signal intensity may play an important biological role in mediating a senescence response in some instances. For example, Sarkisian et al. (2007) have shown that high but not low levels of activated H-Ras trigger senescence in mammary epithelial cells in vivo. Moreover, in this system, low levels of Ras ultimately triggered tumor formation, but only after active Ras was spontaneously upregulated, and senescence checkpoints were inactivated. These observations suggest that some cell types, at least in the mouse, are not sensitive to low levels of oncogenic Ras activity. Therefore, it is possible that in some early lesions, a single copy of an activated Ras allele might be initially selected for, and that after additional genetic alterations occur (for example, p53 loss), Ras might be amplified or its activity upregulated, further promoting tumorigenesis. This finding may also have important implications relating to the potential inactivation of negative feedback signals during tumorigenesis, to be discussed below.
Mechanisms underlying oncogene-induced senescence
Many genes have been shown to trigger oncogeneinduced senescence, and a subset have been confirmed to do so in vivo as well (Table 1) . Several mechanisms have now been proposed to mediate this process. It should be noted that these mechanisms are not necessarily mutually exclusive. Instead, it is possible that multiple mechanisms cooperate to promote or maintain the senescence response in any given cell type. Nevertheless, some signals may be limiting in response to specific genetic events and/or in different tissue types.
DNA damage and replicative stress Two current models hypothesize that oncogene-induced senescence is caused by an accumulation of DNA damage. One model suggests that DNA damage is caused by an oncogene-driven accumulation of reactive oxygen species (ROS) (Lee et al., 1999) . Certainly, ROS have well-known DNA-damaging effects, and agents that cause accumulation of ROS can trigger cellular senescence, which will be discussed below (Chen et al., 1998; Frippiat et al., 2000) . However, another model suggests that the DNA damage response is triggered by excessive replication caused by a sustained oncogenic signal (Bartkova et al., 2006; Di Micco et al., 2006) . Consistent with this model, Di Micco et al. (2006) have shown that senescent cells stall in S phase, have an augmented number of active replicons and exhibit defects in DNA replication fork progression, resulting in an activation of ATR and ultimately ATM. Moreover, it appears that at least a subset of oncogenes can only trigger senescence if cells are allowed to enter S phase (Bartkova et al., 2006; Di Micco et al., 2006) . However, while DNA damage appears to be one signal that can cause senescence (potentially via both mechanisms), not all oncogenes induce DNA damage (Hemann and Narita, 2007) . Moreover, while inactivation of ATM is sufficient to bypass senescence triggered by some oncogenes in some cell types, other studies demonstrate that additional senescence regulators must also be inactivated, indicating that multiple pathways can be simultaneously engaged .
ROS, p38 and PRAK
As noted above, oncogene-induced senescence has also been proposed to be triggered by the accumulation of ROS. Consistent with this hypothesis, oncogeneinduced senescence can be bypassed in murine cells by growing cells in low oxygen (Lee et al., 1999; Parrinello et al., 2003; MacLaren et al., 2004) . Conversely, hydrogen peroxide is also a well-known senescence trigger (Chen et al., 1998; Frippiat et al., 2000) . Notably, ROS scavengers can suppress senescence in some systems, and inactivation of the seladin-1 gene, which has been proposed to be a sensor of ROS, is also sufficient to bypass Ras-induced senescence in BJ fibroblasts (Lee et al., 1999; Wu et al., 2004) . However, there is some debate relating to how ROS may be mediating its effects. While ROS can induce DNA damage, Sun et al. (2007) have also shown that ROS may trigger senescence via a kinase cascade involving p38 and one of its effector kinases known as PRAK, which can phosphorylate and activate p53. Despite these findings, not all oncogenes increase ROS (for example, Raf, myc; Ray et al., 2006; Dolado et al., 2007) , and it is still unknown whether a single activated Ras allele is capable of inducing sufficiently high levels of ROS. Therefore, the relative involvement of ROS in triggering the senescence response might be dictated by the specific genetic event and the resulting signal intensity.
Senescence-associated heterochromatic foci
The signals discussed so far may all be involved in triggering a growth arrest and initiating a senescence response. However, there is an impressive body of evidence suggesting that the 'irreversibility' of senescence may be mediated by dramatic changes in chromatin through the formation of 'senescence-associated heterochromatic foci' (SAHFs; Narita et al., 2003) . SAHFs accumulate during oncogene-induced senescence through a multi-step process and are thought to suppress stably the expression of E2F target genes via the recruitment of Rb and heterochromatin proteins (Narita et al., 2003; Adams et al., 2007) . Recently, the high-mobility group A proteins have been shown to be essential components of SAHFs and when inactivated, along with p16, result in a bypass of Ras-induced senescence in some cell types (Narita et al., 2006) . It has also been suggested that DNA damage may precede and trigger SAHF formation (Hemann and Narita, 2007) , thereby linking these two processes. However, just as not all oncogenic signals trigger DNA damage, not all signals trigger SAHF formation (Hemann and Narita, Mechanisms of oncogene-induced senescence S Courtois-Cox et al 2007), and some cell types appear to be incapable of forming SAHFs . Nevertheless, more subtle changes in chromatin and transcriptional repression may still be important in mediating the senescence response. Understanding how these processes are inter-related will be an important question for the future.
Negative feedback signaling: every action causes a reaction While much attention has been given to downstream (nuclear) events that function during senescence, less is known about the immediate consequences of oncogenic stress that might be involved in transducing the senescence signal. However, it appears that in addition to activating p53 and Rb, oncogenic events also initiate a coordinated shutdown of intracellular signaling pathways, presumably designed to eliminate the aberrant signal (Courtois-Cox et al., 2006) . Moreover, in response to a persistent oncogenic stimulus, these suppressive signals are amplified and actively promote the senescence response. This discovery was first made in the course of studying the NF1 tumor suppressor. As noted above, one benefit of studying NF1 is that its ablation results in an activation of endogenous levels of Ras. Accordingly, this may be one of the few methods by which the effects of a physiological Ras signal can be easily studied in human cells, which are not readily amenable to strategies involving homologous recombination. Another benefit is that NF1 inactivation represents one of the only signals that trigger dramatically different biological effects in different cell types in vitro, may be because the oncogenic signal is lower and closer to threshold levels. Thus, one can compare the biochemical responses of differentially responding cell types as a means of identifying the critical signals involved in triggering the senescence response. The surprise came when Ras and Ras effector pathways were examined in response to acute NF1 loss in cells that were either sensitive or resistant to this senescence signal (Courtois-Cox et al., 2006) . In MEFs, which became immortalized in response to NF1 deficiency, NF1 ablation triggered a sustained activation of Ras and AKT, as expected. However, in normal human diploid fibroblasts, Ras and its effectors were transiently activated following NF1 inactivation but were potently suppressed shortly thereafter. Ras-GTP and phospho-AKT levels, in particular, were reduced to levels much lower than those observed in normal cycling cells. As noted above, this suppression was in stark contrast to the sustained activation of Ras and Ras effectors in MEFs, suggesting that in sensitive cells, this oncogenic signal was triggering a potent negative feedback response. Notably, an oncogenic Raf allele triggered an even more potent and rapid suppression of Ras and AKT activity, indicating that this was not a unique feature of senescence triggered by NF1 deficiency.
In light of this finding, it should be noted that one of the classical definitions of senescence is that senescent cells are incapable of triggering the expression of genes required for proliferation in response to growth factors (Seshadri and Campisi, 1990) . Does this suggest that there are signals that actively shut off intracellular signaling pathways during the process of senescence? Does a cell respond to an oncogenic insult in a stepwise fashion, by first attempting to eliminate the signal and if unsuccessful inducing senescence? Are these same 'feedback signals' be actively involved in triggering the senescence response?
To assess this possibility, it was reasoned that if suppression of Ras or Ras effector pathways was actively involved in promoting senescence, then the following should be true: (1) suppression of Ras signaling should precede senescence, (2) suppression of Ras or Ras effector pathways alone may be sufficient to trigger senescence, (3) Ras suppression should activate known regulators of the senescence pathway (Rb and p53), (4) suppression of Ras signaling should occur in response to multiple genetic insults and (5) evidence of 'negative feedback' should be observed in benign tumors in vivo. Notably, all criteria were supported by in vitro and in vivo studies (Courtois-Cox et al., 2006) .
Oncogenic signals trigger a multitiered negative feedback signaling network in sensitive cells
Using proteomic and genomic approaches, it was further discovered that cells exposed to an oncogenic insult suppressed Ras signaling in two waves (CourtoisCox et al., 2006) . By using an inducible activated Raf allele, which allows for a more precise kinetic analysis, Ras-GTP levels were found to be dramatically reduced within 30 min of Raf induction. This suppression appeared to be primarily regulated by post-translational events, such as phosphorylation and inactivation of the RasGEF protein SOS, among others. This initial negative feedback response resulted in a significant, but incomplete attenuation of Ras and Ras effector pathways, suggesting that cells might be attempting to neutralize the aberrant signal. However, within 42 h, a global negative feedback signaling network was transcriptionally induced. At least 14 proteins known to directly regulate Ras and Ras effectors were affected, including several RasGAPs, RasGEFs, Sproutys, SPREDs and MAP kinase phosphatases. Importantly, a robust suppression of Ras and AKT activity accompanied this transcriptional program (Figure 1 ).
Do negative regulators of Ras signaling function as tumor suppressors?
These findings suggested that perhaps the ultimate trigger of senescence might not be too much Ras signaling, but instead too little. Importantly, senescence could be induced by recapitulating any one of these negative signals in sensitive cell types (for example, ectopic expression of GAP, Sprouty or FOXO proteins).
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However, because of the functional redundancy of these signals, senescence could not be bypassed by inactivating any single gene in this system. Therefore, the relative importance of any given signal may be better assessed in vivo, through genetic means. Nevertheless, it is tempting to speculate that some of these genes might be mutational targets in human cancer. Indeed, a number of genes that negatively regulate the Ras pathway have already been implicated in tumorigenesis; however, there is still much to be learned about these negative regulatory signals, both in the context of normal growth control and tumor suppression (Figure 1 ).
Additional reports also support the hypothesis that negative feedback signals function to suppress tumor development and may do so in a tissue-dependent manner. For example, in the process of generating a mouse model of intestinal tumors, Sansom et al. (2006) showed that the expression of a single, activated K-ras allele was insufficient to trigger AKT or ERK activation in the intestine and reported that negative feedback pathways were responsible for attenuating the Ras signal. In contrast, in the same mouse strain, this single K-ras allele resulted in potent ERK and AKT activation in the kidney and potently cooperated with APC Figure 1 Negative regulators of the Ras pathway. The Ras pathway is one of the most commonly deregulated pathways in human cancer. However, while the positive components that function in the Ras pathway have been well studied, much less is known about the signals that terminate Ras signaling. A variety of oncogenic signals have been shown to trigger a global negative feedback signaling network in normal cells and in benign human tumors. Thus, it appears that the same signals that are utilized to normally attenuate growth factor signaling are coordinately recruited in an attempt to neutralize an oncogenic insult. Moreover, in 'sensitive' cell types, these signals can eliminate the oncogenic threat altogether by promoting cellular senescence. This cartoon includes many, but not all, negative regulators of Ras signaling (shown in red). Boxed proteins have been shown to be upregulated during oncogene-induced senescence, with the exception of exchange factors, which are downregulated. Importantly, ectopic expression of many of these genes triggers senescence in sensitive cells. Proteins that are bolded and red have been shown to play a role and/or be mutated in human cancer. Note that each protein name may represent multiple genes (for example, there are 14 RasGAPs, 4 Sproutys, 2 PHLPPs and so on).
Mechanisms of oncogene-induced senescence S Courtois-Cox et al mutations to drive renal cell carcinoma, illustrating an inherent difference in 'sensitivity' between these two cell types in vivo (Sansom et al., 2006) . It is now becoming more generally apparent that many mouse tissues designed to express this single K-ras allele do not exhibit much if any ERK and AKT activation (Kim et al., 2005) . In contrast, when these mice are crossed to other tumor-prone strains to generate animals with compound mutations, the resulting tumors do exhibit activation of Ras effectors, implying that this suppression is somehow alleviated in the course of tumor development and/or progression (Dinulescu et al., 2005; Hingorani et al., 2005) .
Sprouty family proteins as tumor suppressors
A more direct assessment of negative feedback signaling in tumor suppression has now been performed (Shaw et al., 2007) . Specifically, Shaw et al. (Shaw et al., 2007) showed that activation of a single mutant K-ras allele in the lung resulted in a dramatic upregulation of Sprouty 2, an established negative regulator of Ras signaling (Kim and Bar-Sagi, 2004; Shaw et al., 2007) . Moreover, tumors that expressed high levels of Sprouty exhibited a low histological grade and little ERK activation (Shaw et al., 2007) , and would be presumed to be senescent, on the basis of other published studies (Collado et al., 2005) . Strikingly, genetic inactivation of Sprouty 2 potently enhanced Ras-mediated lung tumorigenesis, affecting tumor number, latency, size and grade, and ERK activation (Shaw et al., 2007) . Thus, these results provide compelling genetic evidence that the Ras-Sprouty feedback loop can suppress tumorigenesis in the lung.
Additional reports indicate that Sprouty and Sproutyrelated proteins may play a tumor suppressor role in other tissues as well. As noted above, multiple Sprouty genes were shown to be induced in response to NF1 loss in senescent cells in vitro (Courtois-Cox et al., 2006) . Consistent with the hypothesis that Sprouty may also function to attenuate the effects of NF1 mutations, Sprouty has been shown to be downregulated in human malignancies associated with NF1 as compared to cognate premalignant lesions (neurofibromas) (Holtkamp et al., 2004) . Moreover, the Sprouty-related gene SPRED 1 has recently been reported to be genetically inactivated in a syndrome with features similar to NF1 (Brems et al., 2007) . Sprouty genes have also been shown to be suppressed in breast, prostate and lung cancer (reviewed in Lo et al., 2006) , providing circumstantial evidence that Sprouty proteins could play a broader role in tumor suppression. However, in all cases, the mechanism by which these genes are downregulated is still unknown. Finally, another intriguing observation consistent with a role for negative feedback signaling in tumor suppression is the observation that suppression of WNT signaling may also participate in the senescence response (Ye et al., 2007) . While the specifics of this study will not be discussed in this review, this finding further suggests that the senescence network is quite complicated and that there is still much that remains to be discovered.
The PI3K pathway and cellular senescence: does too much or too little trigger senescence?
It should be noted that while suppression of Ras (and WNT) signaling can trigger senescence, negative feedback signals might generally function to suppress tumor development by inhibiting proliferation, even in the absence of a full-blown senescence response. Nevertheless, studies performed by Courtois-Cox et al. (2006) demonstrated that in normal human diploid fibroblasts, suppression of the PI3K pathway, but not the MEK/ ERK pathway, is sufficient to induce senescence. This finding is consistent with the long-standing observation that PI3K-deficient MEFs cannot be established, as they rapidly become senescent in culture (Brachmann et al., 2005) . In addition, mutant Raf alleles were found to be extremely potent inhibitors of PI3K signaling, providing an attractive explanation for why mutations in the Raf and PI3K pathway commonly cooperate in tumorigenesis (Meier et al., 2005; Ogawa et al., 2005) .
On the surface, this model appears to contradict findings indicating that activation of PI3K, through loss of PTEN, also triggers senescence (Chen et al., 2005) . Indeed, PTEN inactivation does trigger a sustained activation of AKT in vitro, as determined by examining total phospho-AKT levels (Chen et al., 2005; CourtoisCox et al., 2006) . However, these data do not exclude the possibility that a negative feedback event may occur somewhere downstream of cytoplasmic AKT activation. In fact, several observations are consistent with this possibility. Inactivation of PTEN in the mouse prostate has been shown to result in neoplastic (PIN) lesions that are senescent (Chen et al., 2005) . However, while AKT is phosphorylated in these lesions, it is exclusively cytoplasmic (Trotman et al., 2003) . In contrast, in more advanced lesions caused by compound mutations in PTEN and PML, active AKT is found in the nucleus (Trotman et al., 2006) . Does this suggest that there are suppressive signals that restrict active AKT from the nucleus in senescent cells? Consistent with this possibility, PML has been reported to promote the dephosphorylation of nuclear AKT via recruitment of PP2A (Trotman et al., 2006) . Accordingly, along with promoting the development of more advanced tumors in the PTEN model, loss of PML results in the nuclear accumulation of activated AKT and inactivation of FOXO-3a, a nuclear target of AKT (Trotman et al., 2006) . These observations raise the intriguing possibility that the key negative feedback signals in response to PTEN loss may function to suppress nuclear AKT activity (or localization). Accordingly, nuclear AKT targets might be critical for mediating the senescence response.
Consistent with this possibility, a constitutively active FOXO mutant, deficient in its ability to be phosphorylated by AKT, has been shown to be a potent activator of senescence in sensitive cell types (Courtois-Cox et al., 2006) . In addition, transcriptional reporter assays have shown that FOXO is rapidly activated by Raf, before senescence (Courtois-Cox et al., 2006) . These observations suggest that FOXO may be a critical regulator of oncogene-induced senescence in some settings. Given that FOXO is a tumor suppressor, these observations predict that Raf and FOXO mutations (or inactivation) might cooperate in human cancer. In a surprising twist, Paik et al. (2007) have also found that Sprouty 2 is a direct target of FOXO , raising the possibility that a positive feedback loop may function within this negative feedback pathway. More simply put, once a threshold inhibitory response is achieved, perhaps an irreversible signaling loop designed to terminate intracellular PI3K signaling is engaged to drive or promote a senescence response.
A unified model: all roads lead to Rb and p53
Despite the complexities of oncogene-induced senescence, there is solid evidence that each of the aforementioned pathways play a critical role under some experimental contexts. The unifying theme is that all signals trigger the activation of p53 and Rb, and may do so via multiple proteins (ATM, p38, Arf, Hdm2, p16 and FOXO). However, mere activation of Rb and p53 is not sufficient to trigger senescence. For example, Rb and p53 are activated in quiescent cells, but quiescence is distinct from senescence and is reversible. Perhaps this indicates that a specific threshold or duration of p53 and Rb activation must be achieved to induce a senescence response. Consequently, a threshold signal might require the collaboration of multiple signals that function with different kinetics. Moreover, additional signals, perhaps involving chromatin remodeling, may be required to 'lock in' the growth arrest (Figure 2) , as previously suggested. If this is the case, then it would be expected that signal intensity, tissue type and the microenvironment might all play a role in potentiating or suppressing a senescence response. This may imply that in vivo studies aimed at recapitulating the precise genetic events that occur in human cancer in appropriate cell types may ultimately provide critical mechanistic insight into this process.
If there are so many signals that trigger oncogene-induced senescence, why do humans develop cancer?
The earliest in vitro studies demonstrated that oncogeneinduced senescence could be bypassed by inactivating Rb and p53 (Serrano et al., 1997) . Accordingly, if p53 and/or Rb are inactivated in a cell before an oncogenic event, senescence should be averted. This hypothesis is supported by numerous in vivo mouse modeling studies and by genetic analysis of human tumors. However, Rb and p53 inactivations are not always the first genetic alterations in human cancer, indicating that there must be additional factors that dictate the sensitivity or resistance to senescence signals. Could this mean that each cell type is pre-programmed with a specific oncogenic sensing network? Furthermore, could the differentiation state of a given cell type impact sensitivity or resistance? If so, are some cancer stem or progenitor cells inherently resistant to oncogeneinduced senescence? Answering these questions may provide an important insight into how senescence both functions and in some cases fails to suppress human tumor development. In addition, by gaining a more thorough understanding of the mechanisms that control senescence, we may be able to more effectively design therapies that are capable of triggering this response. Replicative stress, ROS, suppression of intracellular signaling pathways and chromatin remodeling via SAHF formation have all been proposed to regulate the senescence response. This cartoon illustrates how these signals may cooperate to do so. Note that all senescence triggers (ROS, replicative stress and suppression of Ras/ PI3K signaling) can activate Rb and p53. In response to physiological oncogenic stress caused by specific genetic alterations, multiple pathways may be required to cooperate to achieve a threshold and/or sustained activation of Rb and p53. Once this occurs, chromatin remodeling may 'lock in' the growth arrest. SAHF, senescence-associated heterochromatic foci.
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